Search

Duke University researchers and physicians are set to launch a multipronged attack against HIV and employ clinical strategies never before tested. Using a $4 million grant from the U.S. National [...]

Protease inhibitors - a new class of experimental AIDS drugs that are the latest, greatest hope of the research community - have shown promise in early clinical trials. Researchers from [...]

Bristol-Myers Squibb Enrollment in a major Phase II/III clinical trial of d4T has reached 500 participants, according to the drug's manufacturer. The one-year trial, which began in May 1992, has [...]

AUTHORS: RFA Available: AI-91-07. National Institute of Allergy and Infectious Diseases. Letter of Intent Receipt Date: June 5, 1991. Preapplication Meetings: June 3, 4 and 5, 1991. Application Receipt Date: [...]

University of California, San Francisco Measuring the level of two "surrogate markers" in the blood of patients infected with HIV may allow faster determination of which antiviral medications will extend [...]

2002 NOV 4 - (NewsRx.com & NewsRx.net) -- An L-nucleoside antiviral agent, administered orally once daily, rapidly produced potent antihepatitis B virus (HBV) activity in patients chronically infected with HBV, [...]

(CW HENDERSON PUBLISHER www.newsfile.com) -- Chronimed Inc., Minneapolis, Minnesota, announced that it has signed a contract with Visible Genetics Inc., whereby Chronimed's wholly-owned subsidiary, Clinical Partners, will manage Visible Genetics' [...]

Delatribonniere, X.; Dufresne, M.D.; Alfandari, S.; Fontier, C.; Sobazek, A.; Valette, M.; Ajana, F.; Gerard, Y.; Maulin, L.; Bourez, J.M.; Baclet, V.; Senneville, E.; Vermersh, A.; Mouton, Y. According to [...]

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, October 1, 1998;19(2):135-144. Demeter, L.M.; Meehan, P.M.; Morse, G.; Fischl, M.A.; Para, M.; Powderly, W.; Leedom, J.; Holdenwiltse, J.; Greisberger, C.; [...]

Individuals treated with interleukin-2 (IL-2) plus highly active antiretroviral therapy (HAART) have significantly fewer resting CD4+ T cells in their bloodstream which harbor HIV than patients receiving HAART alone, according [...]

A worldwide open label clinical trial of the investigational anti-HIV drug known as 1592 has begun and is expected to enroll up to 2,400 qualified adult AIDS patients in the [...]

Results of toxicity and pharmacokinetic studies of the antiviral phosphorothioate oligonucleotide ISIS 5320 conducted in cynomolgus monkeys were presented at the American Association for Cancer Research conference, held April 12-16, [...]

BioCryst Pharmaceuticals, Birmingham, Alabama, announced the initiation of a Phase I feasibility study using an oral formulation of BCX-34 for the treatment of HIV in combination with standard antiretroviral therapy. [...]

Shaman Pharmaceuticals, Inc., South San Francisco, California, announced that it has begun patient enrollment in a double-blind, randomized, placebo-controlled Phase II study of Virend. Virend is a topical agent for [...]

According to an abstract submitted by the authors to the 31st Annual Meeting of the European Association for the Study of the Liver, held August 25-29, 1996, in Geneva, Switzerland, [...]

The Immune Response Corp., Carlsbad, California, announced that it has begun a 32-week Phase II combination drug trial combining Remune with triple antiviral drug therapy consisting of AZT, 3TC, and [...]

Isis Pharmaceuticals, Carlsbad, California, announced the beginning of Phase I clinical trials of ISIS 5320, an anti-HIV compound. ISIS 5320 is the first product to enter clinical trials from Isis' [...]

Preliminary data suggest that the combination of the investigational antiretroviral agents 1592U89 and 141W94 may be an effective treatment for HIV infection. Initial results from an ongoing small Phase I/II [...]

Unimed Pharmaceuticals, Inc., Buffalo Grove, Illinois, announced the U.S. Food and Drug Administration has expanded the Orphan Drug designation for nitazoxanide (NTZ) from HIV positive and AIDS patients to all [...]

Gilead Sciences, Inc., Foster City, California, announced the commencement of human clinical studies of PMPA. In preclinical testing, PMPA has demonstrated potent activity against simian immunodeficiency virus (SIV) infection, a [...]

Protein Design Labs, Inc. (PDL), Mountain View, California, announced that the Studies of the Ocular Complications of AIDS (SOCA) group decided to stop enrollment and treatment in the Phase II/III [...]

Gilead Sciences, Inc., Foster City, California, announced the commencement of a Phase II/III pivotal human clinical study of its orally administered product candidate GS 840 (adefovir dipivoxil) in patients with [...]

At the same time its anti-HIV properties were announced, a new drug entered clinical trials in Europe. The drug, 1,1'-azobisformamide or ADA, is an azoic compound with a molecular weight [...]

Agouron Pharmaceuticals, Inc., La Jolla, California, provided updated information concerning the anti-viral activity of its anti-HIV drug Viracept (nelfinavir mesylate, formerly AG1343) from two pilot Phase II trials. The report [...]

Medical Discoveries, Inc., Salt Lake City, Utah, announced the creation of a six-member African-American advisory board to oversee the testing and licensing of the company's patented anti-viral drug on the [...]

A new type of non-nucleoside reverse transcriptase inhibitor (NNRTI) has recently entered clinical trials, according to a report at the 2nd National Conference on Human Retroviruses and Related Infections, held [...]

Isis Pharmaceuticals, Carlsbad, California, announced that data were presented showing that ISIS 5320 inhibits HIV viral replication in the SCID-hu mouse model of HIV infection, developed by Systemix Inc. The [...]

The sCD4-toxin chimeric protein CD4-PE40 showed no antiviral effect in a Phase III open-label study involving 21 HIV-infected people. Researcher Rani V. Ramachandran and colleagues of California's Stanford University and [...]

Industry News A potential new antiviral agent, being developed in a collaborative effort involving scientists at Burroughs Wellcome Company and Emory University, Atlanta, Georgia, has moved into Phase I safety [...]

DATELINE: Study VIMRx Pharmaceuticals Inc. announced that Johns Hopkins University, Baltimore, Maryland, has obtained both Institutional Review Board approval and become officially site-registered with the U.S. National Institutes of Health [...]

Shaman Pharmaceuticals Shaman Pharmaceuticals Inc., South San Francisco, California, reported results from the pilot study of Virend, the company's antiviral compound for the treatment of herpes infections. Overall, the study [...]

Clinical Trials VIMRx Pharmaceuticals, Inc. announced that New York University Medical Center/Bellevue Hospital and Beth Israel Hospital, Boston, Massachusetts are currently opening enrollment of patients for the U.S. National Institutes [...]

DATELINE: Gilead Sciences Gilead Sciences Inc., Foster City, California, announced that it has begun Phase I human clinical testing of its product candidate GS 840 in patients infected with HIV. [...]

Isis Pharmaceuticals Inc. Isis Pharmaceuticals Inc., Carlsbad, California, announced the publication of a scientific paper describing a new anti-HIV compound, ISIS 5320, now in preclinical testing. ISIS 5320 was discovered [...]

DATELINE: ICAAC Results of a placebo-controlled clinical study of the experimental drug Ampligen in people infected with HIV have shown that two indicators of the status of the immune system [...]

DATELINE: California Despite the lack of clear evidence of efficacy, secondary analyses of preliminary data from a Phase II clinical trial of the experimental AIDS drug GLQ223 indicate that patients [...]

DATELINE: State University of New York, Stony Brook Studies of drugs developed to inhibit the replication of HIV are now being conducted at University Hospital at Stony Brook, New York. [...]

VIMRx Pharmaceuticals Inc. announced that the U.S. National Institutes of Health (NIH) will sponsor oral dose HIV human clinical trials with VIMRxyn, VIMRx's lead hypericin-based antiviral compound. The trials, which [...]

Alpha 1 Biomedicals Inc. announced the entry of the final patient in its Phase III clinical trial for chronic hepatitis B. The last patient will be treated for six months [...]

U.S. NIAID The U.S. National Institute of Allergy and Infectious Diseases (NIAID) has opened a trial to compare the anti -HIV efficacy of various combinations of zidovudine (AZT), zalcitabine (ddC) [...]

U.S. NIAID The AIDS Clinical Trials Group (ACTG) of the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has selected six additional candidate sites for the proposed trial of [...]

The following letter, from Alan S. Rosenthal, Senior Vice President, Scientific Affairs, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, was received by AIDS Weekly on February 19, 1993: As you may be [...]

U.S. NIH Gilead Sciences Inc., Foster City, California, announced that it has begun human clinical testing of its drug candidate GS 393, a potential treatment for HIV infection. In the [...]

Gilead Sciences Preliminary findings reported by W. Lawrence Drew, M.D., indicate that GS 504, Gilead Sciences' proprietary compound currently in Phase I/II clinical trials, has demonstrated antiviral activity against cytomegalovirus [...]

SOURCE: Journal of Infectious Diseases, November 1992;166(5):1143-1146. An inhibitor of HIV-1 protease currently in early-stage clinical trials has additive or synergistic interactions with zidovudine (AZT), dideoxycytidine (ddC) or recombinant interferon [...]

The long-awaited Phase I/II clinical trial of a new type of anti-HIV drug is set to begin, investigators announced at the AIDS Clinical Trials Group (ACTG) meeting held November 3-6, [...]

BioChem Pharma The most recent results obtained during Phase I/II clinical trials on BioChem Pharma Inc.'s anti-AIDS compound 3TC continue to be favorable according to the company (see DEPARTMENT Research [...]

University of California, Los Angeles A new chemotherapeutic agent, CD4-PE40, is being tested at the University of California, Los Angeles, (UCLA) AIDS Institute and three other centers in the U.S. [...]

Upjohn Phase II clinical trials are expected to begin soon for the second-generation CD4 therapeutic agent known as CD4-PE40. The drug is the first anti-HIV drug to employ the strategy [...]

SOURCE: Journal of Acquired Immune Deficiency Syndromes, October 1991; 4(10):945-951. The lipid mixture AL-721 demonstrated no anti-HIV or immunorestorative efficacy in an eight-week, 40-subject clinical trial. AL-721 and related substances [...]